Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012

American Heart Journal

Volumn 168, Issue 3, 2014, Pages

  Hess, Paul L ^a   Mirro, Michael J ^b   Diener, Hans Christoph ^c   Eikelboom, John W ^d   Al Khatib, Sana M ^a   Hylek, Elaine M ^e   Bosworth, Hayden B ^a,f   Gersh, Bernard J ^g   Singer, Daniel E ^h   Flaker, Greg ⁱ   Mega, Jessica L ^j   Peterson, Eric D ^a   Rumsfeld, John S ^k   Steinberg, Benjamin A ^a   Kakkar, Ajay K ^l   Califf, Robert M ^a   Granger, Christopher B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Parkview Health System   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d MCMASTER UNIVERSITY   (Canada)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Durham Veterans Affairs   (United States)

^g MAYO CLINIC   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MISSOURI   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ANTICOAGULANT THERAPY; AWARENESS; BLEEDING; BLEEDING TENDENCY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEEDBACK SYSTEM; HEALTH CARE; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DISTRICT OF COLUMBIA; DRUG THERAPY, COMBINATION; HUMANS; INSURANCE COVERAGE; PATIENT COMPLIANCE; RISK ASSESSMENT; STROKE; VITAMIN K;

EID: 84908541406     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.04.007     Document Type: Conference Paper

References (66)

1. A.S. Go, E.M. Hylek, and K.A. Phillips et al. Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study JAMA 285 2001 2370 2375
2. A.S. Go, D. Mozaffarian, and V.L. Roger et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association Circulation 127 2013 e6 e245
3. I.M. Ogilvie, N. Newton, and S.A. Welner et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645
4. J.P. Piccini, A.F. Hernandez, and X. Zhao et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure J Am Coll Cardiol 54 2009 1280 1289
5. S.J. Connolly, J. Pogue, and J. Eikelboom et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
6. M. Zalesak, K. Siu, and K. Francis et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin Circ Cardiovasc Qual Outcomes 6 2013 567 574
7. A.F. Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Arch Intern Med 154 1994 1449 1457
8. K. Jackson, B.J. Gersh, and N. Stockbridge et al. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005 Am Heart J 155 2008 829 840
9. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
10. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
11. C.B. Granger, J.H. Alexander, and J.J.V. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
12. K. Kirley, D.M. Qato, and R. Kornfield et al. National trends in oral anticoagulant use in the United States, 2007 to 2011 Circ Cardiovasc Qual Outcomes 5 2012 615 621
13. R.P. Giugliano, C.T. Ruff, and E. Braunwald et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093-04
14. G.Y. Lip, S. Kamath, and M. Jafri Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project Stroke 33 2002 238 242
15. T.S. Harwell, L.L. Blades, and C.S. Oser et al. Perceived risk for developing stroke among older adults Prev Med 41 2005 791 794
16. E. Aliot, G. Breithardt, and J. Brugada et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality Europace 12 2010 626 633
17. M.P. Turakhia, D.D. Hoang, and X. Xu et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study Am Heart J 165 2013 93 101
18. P.J. Devereaux, D.R. Anderson, and M.J. Gardner et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study BMJ 323 2001 1218 1222
19. A.J. Camm, G.Y. Lip, and R. De Caterina et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
20. C.T. January, L.S. Wann, and J.S. Alpert et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 2014 [Epub Mar 28 2014]
21. M.H. Eckman, D.E. Singer, J. Rosand, and S.M. Greenberg Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 4 2011 14 21
22. I. del Conde, and J.L. Halperin Ineligibility for anticoagulation in patients with atrial fibrillation Am J Med 126 2013 105 111
23. J.S. Healey, R.G. Hart, and J. Pogue et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial fibrillation Clopidogrel Trial With Irbesartan for prevention of Vascular Events (ACTIVE-W) Stroke 39 2008 1482 1486
24. S.J. Connolly, J. Eikelboom, and C. Joyner et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
25. 2 and CHAâ-DSâ- VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study Circ Arrhythm Electrophysiol 6 2013 31 38
26. T.J. Wang, J.M. Massaro, and D. Levy et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
27. G.Y. Lip, R. Nieuwlaat, and R. Pisters et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2010 263 272
28. L. Friberg, M. Rosenqvist, and G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study Eur Heart J 33 2012 1500 1510
29. 2 score of 1 who are unlikely to benefit from oral anticoagulant therapy Eur Heart J 34 2013 170 176
30. Z. Hijazi, J. Oldgren, and U. Andersson et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy Circulation 125 2012 1605 1616
31. Z. Hijazi, L. Wallentin, and A. Siegbahn et al. N-terminal pro-b-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) J Am Coll Cardiol 61 2013 2274 2284
32. 2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts Circulation 127 2013 224 232
33. G.J. del Zoppo, and M. Eliasziw New options in anticoagulation for atrial fibrillation N Engl J Med 365 2011 952 953
34. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
35. J.I. Weitz, D.J. Quinlan, and J.W. Eikelboom Periprocedural management and approach to bleeding in patients taking dabigatran Circulation 126 2012 2428 2432
36. R. Sørensen, M.L. Hansen, and S.Z. Abildstrom et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin k antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
37. N. Sarafoff, A. Martischnig, and J. Wealer et al. Triple therapy with aspirin, prasugrel and vitamin k antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation J Am Coll Cardiol 61 2013 2060 2066
38. J.H. Alexander, R.D. Lopes, and S. James et al. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
39. J.L. Mega, E. Braunwald, and S.D. Wiviott et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2011 9 19
40. R. Nieuwlaat, B.J. Connolly, and L.M. Hubers et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study Thromb Res 129 Jun 2012 715 719
41. H.G. Van Spall, L. Wallentin, and S. Yusuf et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial Circulation 126 2012 2309 2316
42. M. Wieloch, A. Sjalander, and V. Frykman et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA Eur Heart J 32 2011 2282 2289
43. T.B. Larsen, L.H. Rasmussen, and F. Skjoth et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study J Am Coll Cardiol 61 2013 2264 2273
44. M.R. Southworth, M.E. Reichman, and E.F. Unger Dabigatran and postmarketing reports of bleeding N Engl J Med 368 2013 1272 1274
45. R. Faria, E. Spackman, and J. Burch et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal Pharmacoeconomics 31 2013 551 562
46. M.R. Patel, A.S. Hellkamp, and Y. Lokhnygina et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) J Am Coll Cardiol 61 2013 651 658
47. K.R. Sepucha Shared decision-making and patient decision aids: is it time? Circ Cardiovasc Qual Outcomes 5 2012 247 248
48. J.S. Healey, S.J. Connolly, and M.R. Gold et al. Subclinical atrial fibrillation and the risk of stroke N Engl J Med 366 2012 120 129
49. N.A. Estes 3rd, J.L. Halperin, and H. Calkins et al. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (writing committee to develop clinical performance measures for atrial fibrillation) developed in collaboration with the Heart Rhythm Society J Am Coll Cardiol 51 2008 865 884
50. P.S. Chan, T.M. Maddox, and F. Tang et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program) Am J Cardiol 108 2011 1136 1140
51. J.P. Piccini, E.S. Fraulo, and J.E. Ansell et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 2011 606 612
52. A.K. Kakkar, I. Mueller, and J.P. Bassand et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) Am Heart J 163 2012 13 19
53. L.A. Smaha The American Heart Association Get With The Guidelines program Am Heart J 148 5 Suppl. 2004 S46 S48
54. A. Avezum, R.D. Lopes, and P.J. Schulte et al. Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study Eur Heart J 34 2013 809 [Abstract Supplement]
55. J.W. Eikelboom, S.J. Connolly, and M. Brueckmann et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med 369 2013 1206 1214
56. J.S. Healey, J. Eikelboom, and J. Douketis et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial Circulation 126 2012 343 348
57. A. Majeed, and S. Schulman Bleeding and antidotes in new oral anticoagulants Best Pract Res Clin Haematol 26 2013 191 202
58. D. Garcia, Y.C. Barrett, E. Ramacciotti, and J.I. Weitz Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants J Thromb Haemost 11 2013 245 252
59. W.I. Gonsalves, V. Gupta, and M.M. Patnaik Management of bleeding complications in patients with new oral anticoagulants J Hematol Transfus 2 2014 1015
60. F. Schiele, J. van Ryn, and K. Canada et al. A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
61. A.C. Bronstein, D.A. Spyker, and L.R. Cantilena Jr. et al. 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report Clin Toxicol (Phila) 50 2012 911 964
62. H. Heidbuchel, P. Verhamme, and M. Alings et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
63. S. Kaatz, P.A. Kouides, and D.A. Garcia et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 Suppl. 1 2012 S141 S145
64. D.B. Matchar, A. Jacobson, and R. Dolor et al. Effect of home testing of international normalized ratio on clinical events N Engl J Med 363 2010 1608 1620
65. C. Heneghan, A. Ward, and R. Perera et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Lancet 379 2012 322 334
66. J.C.P. Weber Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs Adv Inflamm Res 6 1984 1 7